1. Hironori Takagi, Songji Zhao, Satoshi Muto, Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Hikaru Yamaguchi, Hayato Mine, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Ryuzo Kanno, Miho Aoki, Chengbo Tan, Saki Shimoyama, Shigeo Yamazaki, Hajime Kikuchi, Jun Sakakibara-Konishi, Satoshi Oizumi, Masao Harada, Kenji Akie, Fumiko Sugaya, Yuka Fujita, Kei Takamura, Tetsuya Kojima, Osamu Honjo, Yoshinori Minami, Masaharu Nishimura, Hirotoshi Dosaka-Akita, Koji Nakamura, Akihiro Inano, Hiroshi Isobe, Hiroyuki Suzuki. Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004). Lung Cancer. 153:134-142, 2021

 

2. Hironori Takagi, Satoshi Muto, Hikaru Yamaguchi, Hayato Mine, Yuki Ozaki, Naoyuki Okabe, Yuki Matsumura, Yutaka Shio, Hiroyuki Suzuki. Our experience of lung resection in patients who decline blood transfusion for religious reasons. General Thoracic and Cardiovascular Surgery. 69(7):1105-1111, 2021

 

3. Naoyuki Okabe, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Satoshi Muto, Yuki Matsumura, Yutaka Shio, Hiroyuki Suzuki. Pulmonary large call carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: a case report. Thoracic cancer. 12(7):1141-1144, 2021

 

4. Satoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hideaki Nanamiya, Jun-Ichi Imai, Takao Isogai, Shinya Watanabe, Hiroyuki Suzuki. Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden. Oncology Letters. 21(3):203, 2021

 

5. Masayuki Watanabe, Tomohito Higashi, Kana Ozeki, Atsuko Y Higashi, Kotaro Sugimoto, Hayato Mine, Hironori Takagi, Yuki Ozaki, Satoshi Muto, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki, Hideki Chiba. CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma. Scientific reports. 15;11(1):12554, 2021

 

6. Yuki Matsumura, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki. A patient with ALK-positive lung adenocarcinoma who survived alectinib-refractory postoperative recurrence for 4 years by switching to ceritinib. Thorac Cancer. 12(15):2225-2228, 2021

 

7. Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki. CTLA-4 Expression in Tumor-infiltrating Lymphocytes Is Irrelevant to PD-L1 Expression in NSCLC. Anticancer research. 41(12):6267-6272, 2021

 

8. Satoshi Muto, Yuki Ozaki, Takuya Inoue, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki. Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report. Case reports in oncology. 14(1):34-38, 2021

 

9. Nobuhiko Takahashi, Arisa Higa, Gen Hiyama, Hirosumi Tamura, Hirotaka Hoshi, Yuu Dobashi, Kiyoaki Katahira, Hiroya Ishihara, Kosuke Takagi, Kazuhito Goda, Naoyuki Okabe, Satoshi Muto, Hiroyuki Suzuki, Kenju Shimomura, Shinya Watanabe, Motoki Takagi. Construction of in vitro patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. Oncology letters. 21(5):406, 2021

 

10. Mitsuro Fukuhara, Satoshi Muto, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study. Cancer immunology, immunotherapy. Online ahead of print, 2021

 

11. 鈴木弘行. Current Organ Topics: Thorax/Lung and Mediastinum, Pleura: Cancer　肺癌　総括. 癌と化学療法. 48(8):1012-1013, 2021

 

12. 武藤哲史, 鈴木弘行. Thorax/Lung and Mediastinum,Pleura:Cancer 肺癌 局所進行非小細胞肺癌に対する治療戦略の進歩. 癌と化学療法. 48(8):1027-1032, 2021

 

13. 尾崎有紀, 鈴木喜貴, 西山恭子, 錫谷達夫, 鈴木弘行. 免疫チェックポイント阻害薬（抗PD-1 抗体）による免疫療法と腸内細菌叢の関係. 癌と化学療法. 48(9):1096-1099, 2021

 

14. 鈴木弘行, 猪俣頌, 山口光, 峯勇人, 高木玄教, 尾崎有紀, 渡部晶之, 井上卓哉, 福原光朗, 山浦匠, 武藤哲史, 岡部直行, 松村勇輝, 長谷川剛生, 大杉純, 星野実加, 樋口光徳, 塩豊. 非小細胞肺癌に対する周術期治療としての免疫チェックポイント阻害薬の有用性. 肺癌. 61(7):919-923, 2021